Guggenheim Capital LLC Trims Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Guggenheim Capital LLC lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 34.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 15,699 shares of the medical equipment provider’s stock after selling 8,433 shares during the period. Guggenheim Capital LLC’s holdings in Lantheus were worth $1,404,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the third quarter valued at $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the fourth quarter worth about $27,000. Summit Securities Group LLC purchased a new position in shares of Lantheus in the fourth quarter valued at approximately $37,000. UMB Bank n.a. increased its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after buying an additional 280 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,109 shares of company stock worth $6,016,046. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

LNTH has been the subject of several research reports. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $100.62 on Tuesday. The stock’s 50-day simple moving average is $95.76 and its 200-day simple moving average is $95.33. The firm has a market capitalization of $6.89 billion, a PE ratio of 16.74 and a beta of 0.20. Lantheus Holdings, Inc. has a fifty-two week low of $62.59 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.